JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bradley, J. D.
Right arrow Articles by Siegel, B. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bradley, J. D.
Right arrow Articles by Siegel, B. A.
Journal of Nuclear Medicine Vol. 45 No. 1 (Suppl) 96S-101S
© 2004 by Society of Nuclear Medicine

Implementing Biologic Target Volumes in Radiation Treatment Planning for Non-Small Cell Lung Cancer

Jeffrey D. Bradley, MD1,3, Carlos A. Perez, MD1,3, Farrokh Dehdashti, MD2,3 and Barry A. Siegel, MD2,3

1 Department of Radiation Oncology, Mallinckrodt Institute of Radiology, St. Louis, Missouri
2 Department of Radiology, Mallinckrodt Institute of Radiology, St. Louis, Missouri
3 Alvin J. Siteman Cancer Center, Washington University School of Medicine, St. Louis, Missouri

18F-FDG PET offers the radiation oncology community the ability to incorporate biologic information into radiation therapy targets. To date, most of the work in this arena has involved patients with non–small cell lung cancer (NSCLC). The literature suggests that biologic targeting with PET alters the radiation treatment volume significantly in 30%–60% of NSCLC patients for whom definitive therapy is planned. This is mostly the result of the incorporation of regional nodes with 18F-FDG avidity that were previously judged to be uninvolved by CT criteria. The development of the integrated PET/CT scanner is a valuable tool that improves diagnostic accuracy for staging this disease and will increase the accessibility of PET for radiation treatment planning. Its implementation into radiation treatment planning requires strong collaboration between radiation oncologists and nuclear physicians. In this report, we will review the literature on PET-based radiation treatment planning, its potential benefits, and future challenges.

Key Words: PET/CT • non–small cell lung cancer • radiation therapy




This article has been cited by other articles:


Home page
 JNMHome page
R. A. Bundschuh, A. Martinez-Moeller, M. Essler, M.-J. Martinez, S. G. Nekolla, S. I. Ziegler, and M. Schwaiger
Postacquisition Detection of Tumor Motion in the Lung and Upper Abdomen Using List-Mode PET Data: A Feasibility Study
J. Nucl. Med., May 1, 2007; 48(5): 758 - 763.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
T. M. Blodgett, C. C. Meltzer, and D. W. Townsend
PET/CT: Form and Function
Radiology, February 1, 2007; 242(2): 360 - 385.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
J. Czernin and H. R. Schelbert
Introduction
J. Nucl. Med., January 1, 2007; 48(1_suppl): 2S - 3S.
[Full Text] [PDF]

Home page
 JCOHome page
J. Barentsz, S. Takahashi, W. Oyen, R. Mus, P. De Mulder, R. Reznek, M. Oudkerk, and W. Mali
Commonly Used Imaging Techniques for Diagnosis and Staging
J. Clin. Oncol., July 10, 2006; 24(20): 3234 - 3244.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2004 by the Society of Nuclear Medicine.